Join us on April 6, 2022 10am ET for a special webinar on the Ubuntu trial, hosted by the COVID Advocates Advisory Board (CAAB) and our Coalition to Accelerate and Support Prevention Research (CASPR). Led by the COVID-19 Prevention Network (CoVPN), Ubuntu is a new, landmark COVID-19 vaccine trial in sub-Saharan Africa investigating the efficacy of mRNA vaccines in people living with HIV against the omicron variant.
New COVID-19 Vaccines Trials in Sub-Saharan Africa
COVID-19 GPP Resources: A deep dive for advocates
While there are a number of resources that address stakeholder engagement in COVID-19 research, some may not adequately reflect the needs of advocates. Join a conversation reviewing resources for advocates’ needs and shaping future resources!
This discussion will be moderated by AVAC’s Jessica Salzwedel.
- Role of Advocates in Prevention Trials — Chilufya Kasanada, TALC
- Essential Principals and Practices for GPP Compliance — Cathy Slack, HAVEG
- GPP Resources & Implementation in Solidarity — Nina Gobat, WHO
Breaking Down the Latest in HIV Cure Research: What do new data mean for people living with HIV
Join a conversation with researchers as they break down the recent case of HIV cure, the first among women. Speakers will also provide updates from an ongoing trial studying pediatric remission. Join to learn what these advances mean for science and for people living with HIV.
8am PT / 11am ET / 5pm SAT / 6pm EAT
Featuring:
- Dr. Yvonne Bryson, University of California at Los Angeles
- Dr. Deborah Persaud, Johns Hopkins University
- Bridgette Picou, The Well Project CAB Co-Chair and Columnist “Being Bridgette” Positively Aware Magazine
Join Us This Week for Important Conversations
Three important conversations are happening this week: in HIV cure research, in COVID vaccines and in Good Participatory Practice (GPP). These discussions help set agendas and direct resources, so please consider joining one or all of them. We’ve also included links to important news and publications.
Breaking Down the Latest in HIV Cure Research
Tuesday, 5 April at 11am ET/5pm SAST
At CROI 2022, a number of exciting updates on HIV cure research were announced, including the most recent case of HIV remission after a stem cell transplant. Join a conversation with researchers as they break down the recent case of HIV cure, which is the first such cure in a woman. Speakers will also provide updates from an ongoing trial studying pediatric remission. Join to learn what these advances mean for science and for people living with HIV. Register here.
COVID-19 GPP Resources
Wednesday, 6 April at 9am ET/3pm SAST
While there are some resources that address stakeholder engagement in COVID-19 research, they may not adequately reflect the needs of advocates. Join AVAC and partners for a conversation to discuss advocates’ needs and shape the development of future resources. Register here.
New COVID-19 Vaccines Trials in Sub-Saharan Africa
Wednesday, 6 April at 10am ET/4pm SAST
Join us for a special webinar on the Ubuntu trial, hosted by the COVID Advocates Advisory Board (CAAB) and our Coalition to Accelerate and Support Prevention Research (CASPR). Led by the COVID-19 Prevention Network (CoVPN), Ubuntu is a new, landmark COVID-19 vaccine trial in sub-Saharan Africa investigating the efficacy of mRNA vaccines in people living with HIV against the omicron variant. Register here.
Must Reads
Now Open Access: Stakeholder Engagement Must Overcome Tokenism and More
The ethics review process is a crucial opportunity for stakeholder engagement. A new article by AVACer Jessica Salzwedel, CASPR partner Cathy Slack and other co-authors appears in the Journal of Empirical Research on Human Research Ethics and explores three themes that can make or break effective engagement: “It’s Almost as if Stakeholder Engagement is the Annoying ‘Have-to-do’…”: Can Ethics Review Help Address the “3 Ts” of Tokenism, Toxicity, and Tailoring in Stakeholder Engagement?
Possibility of Voluntary Licensing for Injectable Cabotegravir for PrEP
Over the past month AVAC has worked with a wide range of advocates calling for faster and more strategic introduction of injectable PrEP, and several public statements were released. Read statements from a leading group of Southern African Women Advocates and two from AfroCAB: Communities demand ViiV/GSK accelerate access to CAB-LA in LMICs and ViiV continues to not meet our demands to ensure CAB-LA is accessible for our communities. Then today, Viiv Healthcare, the maker of injectable cabotegravir, announced that it is working with the Medicines Patent Pool (MPP) to outline a path forward for voluntary licensing of their product. ViiV said this path will include “an assessment of future demand and necessary manufacturing capacity and capability as well as upstream requirements for potential generic manufacturing partners.” Stay tuned for our updated call to action and roadmap to ensure injectable PrEP and the dapivirine vaginal ring get introduced faster and more strategically.
New Episode of Px Pulse: Getting Rollout Right for Ring and Injectable PrEP
At AVAC, we’ve been calling for coordinated planning to introduce and rollout new prevention products, while expanding access to existing options. We’ve said that these efforts must move much faster than they have in the past, and learn from the lessons of rolling out oral PrEP. So what matters right now for rolling out the Dapivirine Vaginal Ring and injectable cabotegravir as additional PrEP options? Find out in our latest episode of Px Pulse!
Until now, daily oral PrEP, first approved in 2012, has been the only drug-based strategy for HIV prevention. So now it’s time to take the next steps to deliver these new options.
In this episode of Px Pulse, Linda-Gail Bekker from South Africa’s Desmond Tutu Health Foundation and Lillian Mworeko from the International Community of Women Living with HIV East Africa (ICWEA) join host Jeanne Baron and AVAC’s Executive Director Mitchell Warren to discuss innovative models for scale-up and delivery. Taking the right steps now could mean HIV prevention options fulfill their life-saving, epidemic-ending potential, and to do so requires working faster and more efficiently than ever before. We dive into what lessons the field has learned, what’s still off-track, and the steps advocates, policy makers, drug makers and funders should each take right now to turn efficacious options into effective choices.
For the full podcast episode, highlights, and the archive of previous episodes, visit avac.org/px-pulse. And subscribe on Apple Podcasts, Spotify or wherever you get your podcasts!
Reading, Resources and Webinars
At AVAC, we are seeing remarkable new developments and opportunities to engage in HIV and COVID research, development and advocacy. Here is a round-up of what’s been happening, essential reading and resources to help in your advocacy efforts, and some upcoming webinars to join.
In PrEP
Dapivirine Vaginal Ring Approved in South Africa
The South African Health Products Regulatory Authority (SAHPRA) approved the monthly dapivirine vaginal ring for use by women to reduce their HIV risk. South Africa joins Zimbabwe as the first countries to announce approval of the ring, which is already recommended by the World Health Organization as an additional prevention option. The ring’s developer, the International Partnership for Microbicides, has also submitted additional applications for review by several other Eastern and Southern African countries, and advocates are actively engaged in making the ring accessible, including the fabulous new EmpoweRing campaign from our colleagues at ICWEA. AVAC’s Nandi Luthuli told Herald Live, “we know that the most effective intervention is the one someone picks for themselves among an array of effective choices.”
Updates on Injectable Cabotegravir for PrEP
Following US FDA approval of injectable cabotegravir for PrEP in December, there has been a cascade of activities—and a huge need for advocacy! Multiple additional regulatory agencies are reviewing the application; WHO convened their Guidelines Review Group meeting earlier this month, and guidelines are expected mid-year; and Unitaid announced funding for the first two implementation science projects to introduce injectable PrEP, in Brazil and South Africa. A key lesson from oral PrEP over the past decade has been the essential role of civil society; and advocates released a number of important statements—AfroCAB released two sign-on statements: Communities demand ViiV/GSK accelerate access to CAB-LA in LMICs and ViiV continues to not meet our demands to ensure CAB-LA is accessible for our communities, and a leading group Southern African women’s health advocates released a statement by Southern African Women Advocates in Advance of ViiV Convening. Stay tuned for our updated call to action and roadmap to ensure injectable PrEP and the ring get introduced faster and more strategically.
In Vaccines
New HIV Vaccine Study Using mRNA Platform Launched
The NIH also announced a new study to test three mRNA-based HIV vaccine candidates. This study follows an announcement in January from IAVI about another mRNA-based HIV vaccine study. AVAC is preparing a suite of materials on the latest in HIV vaccine research, development and advocacy for HIV Vaccine Awareness Day in May, so stay tuned. In the meantime, check out this snapshot that compares the two studies.
In COVID
New Resources for Journalists
The COVID-19 pandemic spawned an infodemic inside the onslaught of COVID-related information. Journalists struggle to identify reliable information in the everchanging pandemic landscape. With support from the Rockefeller Foundation, AVAC is expanding our partnership with Internews and our Media Cafe program conveners to support journalists covering HIV prevention science to include reporting on COVID. Check out the curated resources to help journalists find high-quality, understandable information.
WEBINAR: COVID-19 GPP Resources, 6 April at 9am ET/3pm SAST
While there are some resources that address stakeholder engagement in COVID-19 research, they may not adequately reflect the needs of advocates. Join AVAC and partners for a conversation to discuss advocates’ needs and shape the development of future resources. Register here.
WEBINAR: New COVID-19 Vaccines Trials in Sub-Saharan Africa, 6 April at 1oam ET/4pm SAST
Join us for a special webinar on the Ubuntu trial, hosted by the COVID Advocates Advisory Board (CAAB) and our Coalition to Accelerate and Support Prevention Research (CASPR). Led by the COVID-19 Prevention Network (CoVPN), Ubuntu is a new, landmark COVID-19 vaccine trial in sub-Saharan Africa investigating the efficacy of mRNA vaccines in people living with HIV against the omicron variant. Register here.
In Cure
WEBINAR: Breaking Down the Latest in HIV Cure Research, 5 April at 11am ET/5pm SAST
At CROI 2022, a number of exciting updates on HIV cure research were announced, including the most recent case of HIV remission after a stem cell transplant. Join a conversation with researchers as they break down the recent case of HIV cure, which is the first such cure in a woman. Speakers will also provide updates from an ongoing trial studying pediatric remission. Join to learn what these advances mean for science and for people living with HIV. Register here.
In Integration of Sexual Reproductive Health and HIV
WEBINAR: Consultation on the Dual Prevention Pill, 12 April at 8:30am ET/2:30pm SAST
Join FP2030 and AVAC for a conversation about The Dual Prevention Pill (DPP), a daily oral pill that is currently being developed for the simultaneous prevention of unintended pregnancy and HIV acquisition. This consultative webinar will highlight unique perspectives from stakeholder in the fields of family planning and sexual & reproductive health. Register here.
Just Published: Catalyzing action on HIV/SRH integration: lessons from Kenya, Malawi, and Zimbabwe to spur investment
We’re excited to announce this new publication – Catalyzing action on HIV/SRH integration: lessons from Kenya, Malawi, and Zimbabwe to spur investment – in the Global Health Action journal. This publication builds on the partnership between our HIV Prevention Market Manager project, ministry of health officials in Kenya, Malawi and Zimbabwe, and Georgetown University’s Center for Innovation in Global Health, and is a call to catalyze actions by development partners in support of national strategies to integrate HIV and SRH information and services.
We hope these resources offer you the context and tools you need to use your passion and add your voice to the work ahead.
New COVID-19 Vaccines Trials in Sub-Saharan Africa
Join us on March 16, 2022 10am ET for a special webinar on the Ubuntu trial, hosted by the COVID Advocates Advisory Board (CAAB) and our Coalition to Accelerate and Support Prevention Research (CASPR). Led by the COVID-19 Prevention Network (CoVPN), Ubuntu is a new, landmark COVID-19 vaccine trial in sub-Saharan Africa investigating the efficacy of mRNA vaccines in people living with HIV against the omicron variant.
Register here.
Announcing the 2022 AVAC Advocacy Fellows
AVAC is delighted to announce the 2022 AVAC Advocacy Fellows, marking the 12th class of the flagship Fellows Program. This group of eight advocates will participate in an 18-month program that supports their advocacy efforts, invests in the further development of their skills, shapes the agenda for HIV prevention research, and influences how quickly new interventions move into policy and programs in their communities and countries.
In response to the success of the program in its first decade and a comprehensive evaluation to expand and improve on that foundation, the program will now run for 18 months, enabling extended support to Fellows’ advocacy priorities. In addition, the program will strengthen the role of the alumni network in the program and strengthen the linkages between organizational partners.
The 2022 Fellows were selected from a pool of 140 applicants from 12 countries. The 2022 Advocacy Fellows and their host organizations include:
- Ruth Akulu, International Community of Women Living with HIV Eastern Africa, Uganda
- Onward Chironda, Gays and Lesbians of Zimbabwe, Zimbabwe
- Catherine Madebe, Mulika Tanzania, Tanzania
- Prince Mikel Juao, Lesbians Intersex Trans and other Extensions, Malawi
- Natasha Mwila, The Network of Zambian People Living with HIV/AIDS, Zambia
- Peter Ntheri, Lesotho Network of AIDS Service Organization, Lesotho
- Elizabeth Onyango, Coast Sex Workers Alliance, Kenya
- Liyema Somnono, Passionate Unlimited Peers in Action, South Africa
Please visit the Advocacy Fellows page to learn more about their planned work for the year. We hope you’ll find ways to collaborate with them in 2022 and beyond.
We are also extremely proud of the important achievements of the recently graduated Fellows of 2020/21. Their evidence-based advocacy focused on critical areas and marked significant progress to help accelerate ethical research and equitable access to HIV prevention options. Advocacy like this overcomes historic barriers to HIV prevention and represents a foundation the field must continue to invest in to finally end the epidemic. Keep watching this space to learn how the 2022 Fellows and the alumni Fellows carry this vital work forward.
Thank you to all of the applicants and their proposed host organizations for the time and effort put into the application process, and to the independent review committee of advocates, scientists and former Fellows and hosts who guided our decision-making.
2020/21 Fellows Update
The AVAC Advocacy Fellows Program, launched in 2009, fosters a network of deeply-informed, skilled and confident advocates to strengthen and expand advocacy for HIV prevention locally, regionally and globally. In the decade since its launch, 83 advocates from 14 countries in Africa and Asia have been through this program and have gone on to use their evidence-based advocacy to help accelerate ethical research and equitable access to HIV prevention options.
AVAC is tremendously proud of its 2020/2021 class of Fellows whose tenure in the program began during a time of great uncertainty in HIV prevention and in global health. Their tenacity, passion and unwavering commitment to bringing HIV prevention and sexual and reproductive health options and choices that their communities want and need are central tenants to recalibrating global health equity.
Read on for more on their achievements and accomplishments as AVAC Fellows.
Josephine Aseme, Heartland Alliance, Nigeria
Josephine’s advocacy for PrEP rollout in key populations is exemplary; her accomplishments speak to her drive and grit. As an oral PrEP-taking sex worker and founder of Greater Women Initiative for Health and Rights, she has taken the helm, steering Nigeria’s key populations (KP) community to accelerate access to HIV prevention. She trained almost 300 KP champions across select districts in peer-to-peer PrEP education and charted an increase of 23,000+ PrEP referrals as a result.
She successfully worked with the Ministry of Health and her host Heartland Alliance to secure PrEP inclusion in the National Consolidated Service Delivery Guidelines on HIV and STIs for Key Populations, in Nigeria’s National HIV/AIDS Prevention Plan, and in Heartland Alliance’s Peer Educators’ Manual, a nationally recognized compendium. And, as a KP representative to PEPFAR’s country planning, she convinced her peers as well as implementers to add language on the Dapivirine Vaginal Ring and cabotegravir injectables to Nigeria’s country operating plan in 2021.
Chisomo Chaweza, MANERELA+, Malawi
As a KP ally, Chisomo strategically selected MANERELA+, a network of religious leaders, to host him through his Fellow project. This reflects Chisomo’s big-tent approach to advocacy, tapping into all the key sectors to push for accelerated PrEP rollout in key populations. Specifically, he rallied demand for the release of the long-overdue PrEP Guidelines—finally launched in September, 2021.
And when the MOH was not forthcoming with where to find PrEP dispensing sites, Chisomo rallied pressure on PEPFAR to reveal this information. He handled the media as an advocacy tool from both sides—engaging them to consistently and accurately cover HIV prevention and also developing his own blog, Liberty, and writing opinion pieces. He drafted a policy brief Making up for Lost Time: Increasing Access to PrEP and HIV Self-testing for Key Populations in Malawi, which continues to be employed as an advocacy tool today by others such as the incoming 2022 Fellow.
Mandisa Dukashe, Wits RHI, South Africa
During her Fellow’s project, Mandisa became a renowned face of U=U, after launching South Africa’s first treatment as prevention campaign in the Eastern Cape. And she’s well on her way to leading regional advocacy to popularize and formalize the uptake of U=U to promote treatment, adherence and viral load suppression as a way to destigmatize and sexually disinhibit people living with HIV.
Mandisa established alliances with UNAIDS, prominent political leaders and South Africa’s National AIDS Council and collaborated closely with the Southern African HIV Clinicians Society and Prevention Access Campaign to promote U=U. Her work culminated in the organizing of a U=U Satellite session at the SA AIDS Conference and in the formation of the U=U Africa Forum she co-founded with AVAC Fellow Alumni Kennedy Mupeli from Botswana. They continue to advocate for ministries of health to officially implement U=U.
Winifred Ikilai, The National Forum of People Living with HIV/AIDS Networks in Uganda
Wini was the first AVAC Fellow to integrate COVID into her advocacy targets and the pay-off was huge. She successfully engaged social media in spearheading a campaign to secure ARVs, food, hygiene packs and other services and supplies for 2,700 households in 115 districts under lockdown. Her advocacy earned her the 2021 Omololu Falobi Award for Excellence in HIV Prevention Research Community Advocacy while also garnering opportunities to collaborate with IAVI, aidsmap, Aljazeera and others.
What’s more, Wini won big gains for improved HIV treatment literacy and counseling through her creation of the Beyond My Pill Campaign. As part of her advocacy for improved treatment services, she organized a national level dialogue on test and treat, revitalizing the voices of PLHV networks and mobilizing for further PEPFAR spending. She won both recognition and funding to enhance treatment programs, reflected in Uganda’s National HIV and AIDS Strategic Plan 2021/21–2024/25.
Joyce Ouma, National Empowerment Network of People Living with HIV/AIDS in Kenya
Joyce methodically threaded her way through all relevant power centers to influence large-scale integration of SRH and HIV. First, she built a cadre of young women champions who contributed to her successful campaign to win Machakos county-level budget for SRH/HIV integration, and to win further national commitment from PEPFAR COP 21 and Global Fund 2021–2024.
She sat on Kenya’s national HIV/SRH integration working group where they spearheaded the one-stop-shop piloting in five counties. In the midst of Joyce’s Fellow project, the WHO green lighted the Dapivirine Vaginal Ring, so, naturally, Joyce co-convened a civil society taskforce to fast track its introduction. All the while, she penned two opinion pieces in Kenya’s national daily Star speaking of the continued need for a robust HIV prevention pipeline.
Esnart Sikazindu, Community Based TB/HIV AIDS Organisation (CBTO), Zambia
Esnart’s advocacy for differentiated PrEP services played out through social and traditional media. As Zambia moved PrEP out of ART clinics into more youth-friendly spaces, she saw an unfulfilled need to let young women know about PrEP and where to find it. Thus, she spread the word and built demand via social media.
She also took to the airwaves and print to let the general public know about PrEP as well as forthcoming HIV prevention like the PrEP ring and injectable. And not least, Esnart drafted a policy brief Too Little for Far Too Long: A Gap Analysis for Adolescent Girls and Young Women, which continues to be employed as an advocacy tool today.
AVAC Applauds South Africa Approval of Dapivirine Vaginal Ring as HIV Prevention Option for Women
AVAC enthusiastically welcomes the South African Health Products Regulatory Authority’s (SAHPRA) approval of the monthly Dapivirine Vaginal Ring for use by women ages 18 and older to reduce their HIV risk. The Dapivirine Vaginal Ring is a much-needed addition to a proven HIV prevention method mix that also includes male and female condoms, daily oral PrEP, voluntary medical male circumcision (VMMC) and injectable cabotegravir (CAB) in some countries. South Africa joins Zimbabwe as the first countries to approve the ring, which is also under review in several other Eastern and Southern African countries, and is recommended by the World Health Organization as an additional prevention option.
“This is a critical step forward in providing a new prevention option that many South African women need and can use,” said Mitchell Warren, AVAC executive director. “It will be important for South Africa to ensure that the Ring is integrated into HIV prevention guidelines and made available to women as quickly as possible. Regulatory approval of the Ring must be accompanied by strategic, effective and equitable rollout that transforms the growing list of HIV prevention options into real and accessible choices for the women most in need of HIV prevention.”
“We know that the most effective intervention is the one someone picks for themselves among an array of effective choices,” said Nandi Luthuli, AVAC’s Regional Stakeholder Engagement Manager, based in South Africa. “It’s very exciting that South African women will soon have a broader choice in HIV prevention options. More choices can mean more HIV infections averted, which will help South Africa control the HIV epidemic.”
“The SAHPRA approval is a critical step in translating scientific research into public health impact,” said Manju Chatani-Gada, AVAC’s Director of Partnerships and Capacity Strengthening. “We hope that other countries currently reviewing the Ring will follow the examples of South Africa and Zimbabwe and take the necessary steps to provide this important HIV prevention option to women. At the same time, we hope countries reviewing injectable cabotegravir as a new prevention option will move quickly to add yet another proven effective and much needed HIV prevention option to the toolbox.”
“We thank the thousands of women who participated in the trials that provided the evidence that the Ring works as well as dozens of advocates and community members in South Africa and across the globe who have tirelessly advocated for this important new prevention option for women,” Chatani-Gada added.
Developed by the International Partnership for Microbicides (IPM), the monthly Dapivirine Vaginal Ring is a longer-acting HIV prevention product that women can control and use discreetly to reduce the risk of HIV transmission during vaginal sex. Women insert the product themselves and replace it every month. Made of flexible silicone, the ring slowly releases the antiretroviral (ARV) drug dapivirine directly in the vagina at the site of potential infection, with minimal exposure elsewhere in the body. The Ring was proven effective in two Phase III studies, received a positive opinion from the European Medicines Agency (EMA) and is recommended by the World Health Organization (WHO) as a prevention option for women.
Recent data from the REACH Study showed that nearly all of the adolescent girls and young women aged 16-21 in the study accepted the Ring and daily oral PrEP as prevention options and that when young women had access to and experience with two biomedical prevention options, almost all of them chose to continue using one of them – and most of them actually chose to use the dapivirine vaginal ring.
“SAHPRA’s approval for women over 18 is great news, but we hope that soon the ring can also be made available to adolescent girls as young as 16,” said Maureen Luba, AVAC’s Senior Policy and Advocacy Manager and a member of the IPM Board of Directors. “We know that in South Africa and other Eastern and Southern African countries the HIV infection rates among girls and young women are very high in many communities. The Ring could also be an important option to help empower adolescent girls to protect themselves.”
AVAC looks forward to working closely with civil society partners, the South African National Department of Health, IPM, the USAID-funded MOSAIC and CASPR Projects, and many other partners to ensure this regulatory milestone can be rapidly translated into public health impact.